These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2687813)

  • 21. The cost of treating cancer patients: treatments versus reimbursements.
    Goldstein MG
    Md Med; 2011; 12(4):15. PubMed ID: 22455202
    [No Abstract]   [Full Text] [Related]  

  • 22. Access to cancer care and clinical trials: a time for reappraisal.
    Runowicz CD; Berman ML
    Womens Health Issues; 1996; 6(2):112-3. PubMed ID: 8932466
    [No Abstract]   [Full Text] [Related]  

  • 23. Biotherapy: recent advances and nursing implications.
    Mayer DK
    Nurs Clin North Am; 1990 Jun; 25(2):291-308. PubMed ID: 2186383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Costs studies show clinical trials, standard therapy may be equal.
    Reynolds T
    J Natl Cancer Inst; 2000 Jul; 92(14):1116-8. PubMed ID: 10904079
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
    Ozols RF; Herbst RS; Colson YL; Gralow J; Bonner J; Curran WJ; Eisenberg BL; Ganz PA; Kramer BS; Kris MG; Markman M; Mayer RJ; Raghavan D; Reaman GH; Sawaya R; Schilsky RL; Schuchter LM; Sweetenham JW; Vahdat LT; Winn RJ;
    J Clin Oncol; 2007 Jan; 25(1):146-62. PubMed ID: 17158528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Routine patient care in clinical trials: whose cost is it anyway?
    Berlyn D
    J Law Health; 2001-2002; 16(1):77-102. PubMed ID: 14650773
    [No Abstract]   [Full Text] [Related]  

  • 27. Patient care cancer clinical trials at the National Cancer Institute: a resource for payers and providers.
    Pearson D
    Manag Care Q; 2002; 10(1):33-7. PubMed ID: 15988953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer diagnosis related groups.
    Mortenson LE
    Prog Clin Biol Res; 1986; 216():149-54. PubMed ID: 3088594
    [No Abstract]   [Full Text] [Related]  

  • 29. The effect of reimbursement policies on the management of Medicare patients with refractory ovarian cancer.
    Bennett CL; Stinson TJ; Yang T; Lurain JR
    Semin Oncol; 1999 Feb; 26(1 Suppl 1):40-5. PubMed ID: 10071972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Network that oversees cancer trials in the US needs to be streamlined, says report.
    Mayor S
    BMJ; 2010 Jun; 340():c3076. PubMed ID: 20534681
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical trial billing compliance at academic medical centers.
    Boyd CE; Meade RD
    Acad Med; 2007 Jul; 82(7):646-53. PubMed ID: 17595559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical trials. Access and reimbursement.
    Farrar WB
    Cancer; 1991 Mar; 67(6 Suppl):1779-82. PubMed ID: 2001577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reimbursement warfare: who loses?
    MacDonald SA; Brodie K; Winn S; Wilhardt L; Williams T
    Home Healthc Nurse; 1991; 9(6):9-12. PubMed ID: 1787072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncology in the era of managed care.
    Gerszten PC
    J Oncol Manag; 1998; 7(3):21-3. PubMed ID: 10181577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SGR, regulatory issues and GME among topics at National Advocacy Conference.
    Milroy MJ
    S D Med; 2015 Apr; 68(4):143. PubMed ID: 25946890
    [No Abstract]   [Full Text] [Related]  

  • 37. [Choosing effective laboratory tests for hyperlipidemia, and the reimbursement system].
    Takagi Y
    Rinsho Byori; 2002 Mar; 50(3):262-6. PubMed ID: 11985053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The tip of the iceberg: financial liability analysis and clinical trials.
    Baio KT; Takamoto R
    Healthc Financ Manage; 2006 Jun; 60(6):102-4, 106, 108. PubMed ID: 16773995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological response modifier treatment reimbursement: present status and future strategies.
    Yasko JM
    Oncol Nurs Forum; 1988; 15(6 Suppl):28-34. PubMed ID: 3205853
    [No Abstract]   [Full Text] [Related]  

  • 40. Need for standardization of cancer practice via nationally accepted treatment guidelines.
    Kovach JS
    Oncology (Williston Park); 1996 Nov; 10(11 Suppl):41-3. PubMed ID: 8953595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.